Emgality
(Galcanezumab)ApprovedMonoclonal antibody
Eli LillyGalcanezumab is used to prevent migraines by blocking a protein in the body that causes migraine headaches. It is given as an injection and helps reduce how often migraines occur.[2] Emgality is currently approved and in use across 6 indications[4].[1]
Emgality is one of 157 monoclonal antibody programs targeting Migraine Disorder. It is currently in Approved.
6
Indications
31
Total Trials
6
Active Trials
156
Competitors
7
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
105 competitors in Migraine
#DrugCompanyPhaseTrials
1Emgality
Eli LillyApproved
Triptans
PfizerPhase 3
Aspirin /d
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Elismetrep
KKallyope Inc.
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
Tizanidine Hydrochloride
EElan Pharmaceuticals
Phase 3
Bayer Aspirin
BayerPreclinical
Cervidil
PfizerPreclinical
Cymbalta
Jazz PharmaceuticalsPreclinical
Adempas
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine19 trials
Show 16 more trials
Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly
Unknown status·—··NCT04803513·300 enrolled
ART3 trials
Cluster headache3 trials
Headache3 trials
2 more indications
Fibromyalgia1 trial
Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
Completed·—·Phase 4·NCT04158752·26 enrolled
Regulatory
FDA Approval Timeline[5]
Sep 27, 2018
EMGALITY
BLA BLA761063
Sep 27, 2018
EMGALITY
NDA BLA761063
Jun 4, 2019
EMGALITY
NDA BLA761063
Dec 5, 2019
EMGALITY
NDA BLA761063
May 24, 2022
EMGALITY
NDA BLA761063
Mar 21, 2025
EMGALITY
NDA BLA761063
Jun 5, 2026
EMGALITY
NDA BLA761063
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Emgality drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Galcanezumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]